Biogen on Tuesday agreed to pay $165 million ... The Stifel team spoke to physicians, who were clear that the efficacy bar zorevunersen needs to meet is “very high.” ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback